James Burke
James Burke
Approximately 50,000 cases of superficial bladder cancer are diagnosed annually in the United States. Immunotherapy utilizing intravesical BCG is the most effective standard therapy for superficial transitional cell carcinoma of the bladder...
James M Burke
James M Burke
Monoclonal antibody therapy for cancer has significantly altered the natural history of several common cancers. This success was attained only after many years of failure to understand the technical limitations of antibody therapy. In order...
Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses [0.03%]
肿瘤微环境促进溶瘤病毒抗癌效应的研究进展及其机制探讨
Naomi De Silva,Harold Atkins,David H Kirn et al.
Naomi De Silva et al.
Oncolytic viruses (OVs) are selected based on their ability to eliminate malignancies by direct infection and lysis of cancer cells. Originally, OVs were designed to target malignancies by taking advantage of the defects of cancer cells obs...
Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme [0.03%]
疱疹病毒重组体的临床应用制备用于治疗多形性胶质母细胞瘤
Christian Goetz,Matthias Gromeier
Christian Goetz
PVS-RIPO is a genetically recombinant, non-pathogenic poliovirus chimera with a tumor-specific conditional replication phenotype. Consisting of the genome of the live attenuated poliovirus type 1 (Sabin) vaccine with its cognate IRES elemen...
Fabrice Le Boeuf,John C Bell
Fabrice Le Boeuf
There is an urgent need for innovative therapeutic strategies to treat aggressive metastatic cancers that are incurable with standard therapeutic approaches. Novel treatment strategies like oncolytic virotherapy have led, in some cases, to ...
Directing systemic oncolytic viral delivery to tumors via carrier cells [0.03%]
通过载体细胞直接将系统性溶瘤病毒递送至肿瘤中
Hiroshi Nakashima,Balveen Kaur,E A Chiocca
Hiroshi Nakashima
The systemic administration of oncolytic virus (OV) is often inefficient due to clearance of the virus by host defense mechanism and spurious targeting of non-cancer tissues through the bloodstream. Cell mediated OV delivery could hide the ...
Byram W Bridle,Stephen Hanson,Brian D Lichty
Byram W Bridle
The interactions between the immune system, a malignant tumour and an oncolytic virus are complex and poorly understood. For oncolytic viruses to become successful therapeutics we need to better understand these interactions and identify st...
Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics [0.03%]
肿瘤溶瘤病毒的临床试验：从一期走向与标准疗法联合治疗
K J Harrington,R G Vile,A Melcher et al.
K J Harrington et al.
It is time for those working on oncolytic viruses to take stock of the status of the field. We now have at our disposal an array of potential therapeutic agents, and are beginning to conduct early-phase clinical trials in patients with rela...
Marianne M Stanford,John C Bell,Markus J V Vähä-Koskela
Marianne M Stanford
The use of viruses as targeted cancer therapy has shown significant promise, and the list of oncolytic viruses continue to grow. The interest in unexplored viruses as oncolytic agents is a natural corollary to the successes and challenges o...
Jean Rommelaere,Karsten Geletneky,Assia L Angelova et al.
Jean Rommelaere et al.
The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic vi...